ARCHIVES

Economic Analyses Of New Therapies Useful In Phase III Studies, Trialists Say

This article is from The Cancer Letter archive.

Vol. 35 No. 29 | July 24, 2009

Download PDF Visit The Full Archive

Related Articles

ODAC Votes For Accelerated Approval For Adcetris For Two Lymphoma Indications

July 22, 2011

AHRQ Funds Research To Reduce Medical Errors.

October 19, 2001

Henles to Get Bristol-Myers $25,000 Award

March 23, 1979

Funding Opportunities.

July 19, 2002

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

September 26, 2014

Roche Reports New Avastin Results As FDA Mulls Breast Cancer Indication.

February 15, 2008